Wu Shi Tiaozhifang Clinical Studies On Dyslipidemia

ObjectiveChinese herbal compound on blood lipids observed in patients with abnormal lipid Tiaozhifang series and C-reactive protein, confirmed Tiaozhifang for the treatment of dyslipidemia, as well as cardiovascular and cerebrovascular disease prevention role, and to evaluate the safety of the drug.MethodsIn October 2010 to April 2011 in Guangzhou University of Traditional Chinese Medicine, First Affiliated medical clinic, cardiology ward and medical wards treatment of other patients with angina pectoris and 10 in Guangzhou University of Traditional Chinese Medicine, First Affiliated medical examination of healthy people studied。The cases of 60 patients were collected, according to the order of treatment patients were randomly divided into two groups, the treatment group of 30 patients in the control group of 30 patients, the treatment group to the lipid Wu Fang, medication once a day, every 100ml, the control group I Xuezhikang,0.6g/times, once a day, The treatment for 6 weeks, TC, LDL-C, TG, HDL-C, TC-HDL-C/HDL-C, C-reactive protein were observed, and blood routine, urine routine, stool routine, liver and kidney function, electrolytes, transaminase. By comparing before and after treatment in each group after treatment group changes in various indicators of the index changes, the evaluation of lipid Wu lipid side effects and drug safety.ResultTreatment of 6 weeks, Tiaozhifang the clinical treatment of dyslipidemia was 71.3% of the total, with the clinical lipid effects Xuezhikang no significant difference between the two groups in serum total cholesterol (TC), low density lipoprotein (LDL-C), triglycerides ester (TG), high density lipoprotein (HDL-C), C-reactive protein were significantly lower than that before treatment, respectively, compared with before treatment were significantly different (all &1t;0.01), but between the two groups, No statistically significant changes in blood lipids (P> 0.05). Tiaozhifang treatment of dyslipidemia low incidence of adverse reactions, patients and well tolerated.ComclusionTiaozhifang the clinical treatment of dyslipidemia is effective, can effectively increase HDL-C, lower C-reactive protein, can be effective prevention and treatment of cardiovascular and cerebrovascular diseases and related lesions, and the low incidence of adverse reactions have clinical value.